Peer-Reviewed Study on Evvy’s Real World Outcomes Demonstrates Breakthrough in Bacterial Vaginosis Care at Scale

Evvy’s At-Home, Precision Vaginal Healthcare Platform Demonstrates Robust Symptom Resolution and Significantly Reduced Infection Recurrence across >1,000 Patients — Setting a New Standard for BV care.

NEW YORK--(BUSINESS WIRE)--Evvy, leader in vaginal microbiome testing & care, has published the largest real-world outcomes study to date on at-home vaginal healthcare, demonstrating a breakthrough in outcomes for the diagnosis and treatment of bacterial vaginosis (BV). The peer-reviewed study, published in Microorganisms Journal, validates that Evvy’s innovative, personalized approach leads to significantly lower recurrence rates and robust symptom resolution.

Bacterial Vaginosis is a leading reason women seek healthcare, yet the standard of care is underpinned by overly simplistic methods like microscopy and broad-spectrum antibiotics — resulting in high misdiagnosis and recurrence rates. Evvy’s platform reinvents this model by pairing at-home, next-generation vaginal microbiome sequencing with personalized, prescription-based clinical care. This peer-reviewed study demonstrates that Evvy’s approach leads to robust microbiome restoration and improved clinical outcomes at scale.

By bringing together validated metagenomic sequencing (mNGS), detailed symptom assessments, precision care pathways, and licensed clinicians, the study found that:

• 75.5% of patients reported symptom relief at four weeks
• At a mean follow-up of 4.4 months post-treatment (longer in numerous cases), recurrence was 30.0%, versus >50% in traditional pathways — demonstrating effectiveness even in high-recurrence BV populations.
• Patients experienced a significant shift from dysbiosis to Lactobacillus dominance, with significant reductions in BV-associated bacteria like Gardnerella and Prevotella
• Patients achieved clinical and microbial success entirely from home

In a landscape with months-long wait times for OBGYN appointments and over one third of U.S. counties lacking OBGYN care entirely, Evvy can deliver comprehensive testing and clinician-guided treatment to patients anytime, anywhere.

In addition to more comprehensive testing and personalized care pathways, Evvy’s platform demonstrates remarkable patient adherence to treatment, driven by Evvy’s focus on patient engagement. Through one-on-one health coaching, digital treatment tracking, and relevant educational resources, 78% of patients achieved high adherence to their treatment plans, demonstrating that ongoing support is as critical as the initial prescription. This integrated approach empowers women to manage their vaginal health discreetly and with confidence.

“Traditional care has oversimplified vaginal conditions for far too long, resulting in misdiagnoses, repeated courses of antibiotics, and countless women left without answers,” said Dr. Kate McLean, Chief Medical Officer of Evvy. “This study is the first-of-its-kind to show that comprehensive testing and personalized care not only delivers targeted relief, but also restores the vaginal microbiome and prevents recurrence.”

The study builds on Evvy’s recent peer-reviewed validation of its CLIA, CAP, and CLEP-certified Vaginal Health Test, published in Diagnostics, which confirmed 93.1% sensitivity and 90% specificity across 700+ microbes.

About Evvy:

Evvy is closing the gender health gap through novel biomarker discovery in the vaginal microbiome. Evvy’s groundbreaking Vaginal Health Test is the world’s only certified, peer-reviewed test to uncover 700+ microbes with a single, at-home swab. Combined with precision treatment pathways and 1-1 coaching, Evvy provides over 50,000 women with data-driven, personalized healthcare for vaginal infections, fertility, menopause, and more. Evvy has built the world’s largest dataset on the vaginal microbiome, and they are pioneering research across infertility, preterm birth, gynecological cancers, and more.